Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

173.93+0.11 (+0.06%)

At close: 4:00PM EDT

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Commodity Channel Index

View all chart patterns

Performance Outlook

Previous Close	173.82
Open	175.53
Bid	168.00 x 800
Ask	176.00 x 800
Day's Range	173.02 - 175.53
52 Week Range	107.59 - 189.00
Volume	325,316
Avg. Volume	670,611

Market Cap	10.605B
Beta (5Y Monthly)	1.04
PE Ratio (TTM)	19.17
EPS (TTM)	9.07
Earnings Date	Aug 03, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	207.12

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

-19% Est. Return

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

Simply Wall St.
Has Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's Recent Performance Got Anything to Do With Its Financial Health?
Jazz Pharmaceuticals' (NASDAQ:JAZZ) stock up by 4.3% over the past three months. As most would know, long-term...
- Chemed Corporation's (NYSE:CHE) Stock Has Fared Decently: Is the Market Following Strong Financials?
  Simply Wall St.
- Are Driver Group plc's (LON:DRV) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
  Simply Wall St.
Motley Fool
Is Jazz Pharmaceuticals Stock a Buy?
In February, biotech company Jazz Pharmaceuticals (NASDAQ: JAZZ) made some noise when it announced it would acquire GW Pharmaceuticals, a drugmaker specializing in developing cannabidiol (CBD)-derived medicines. The cash-and-stock transaction, which closed in May, was valued at $7.2 billion and represented an almost 50% premium to GW Pharma's market value. While there are good reasons why Jazz Pharma decided to make this move, acquisitions don't always work as planned.
PR Newswire
National Comprehensive Cancer Network® Adds Newly Approved Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the National Comprehensive Cancer Network® (NCCN) added Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to the Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia (ALL), for both pediatric and adult patients.